Xencor, Inc.

Xencor, Inc.

XNCRNYSE / NASDAQHealthcareSmall cap

$33.26-$0.75 (-2.2%)

Last close · Data as of Nov 20, 2026

Market cap
$890.4M
Revenue
$125.6M
Net margin
-73.2%
ROCE
-7.6%

+113.5% over the last year

Xencor, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+33.4%
3M
+23.2%
6M
+193.8%
1Y
+113.5%
5Y
-9.8%

52-week range

Day change -$0.75 (-2.2%) from $34 to $33 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in XNCR, bought on each weekday since 2021.

News & filings

What Xencor filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 91.9 million US dollars in fiscal 2025.

Strengths (1)

  • Cash on the balance sheet equals 62% of the company's market value.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.

Read moreShow less

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Sector
Healthcare
Shares outstanding
71.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$890.4M
P/B
1.4x
EV / Sales
4.2x
P/S
7.1x
52-week high
$39.97
52-week low
$10.41

Profitability

Operating margin
-141.3%
Net margin
-73.2%
EBITDA margin
-37.6%
ROE
-14.5%
ROCE
-7.6%
ROA
-10.5%
Asset turnover
0.14

Growth

Revenue
$125.6M
Revenue growth, 1Y
13.7%
Revenue CAGR, 3Y
-8.6%
Net profit growth, 1Y
-60.5%
Free cash flow
-$138.3M

Solvency

Current ratio
6.25
Debt / Equity
0.30
Debt / Assets
0.21
CFO / Net profit
1.47
Cash / Market cap
61.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$125.6M
Gross profit$125.6M
Operating expenses$303.1M
Research and development$239.4M
Selling, general and administrative$63.6M
Operating income-$177.5M
Interest and other$87.9M
Pretax income-$89.6M
Tax and other$2.3M
Net income-$91.9M

Revenue and net profit

Revenue grew 13.7% in FY2025; net profit is the dashed line.

Xencor, Inc. revenue and net profit by fiscal year
Xencor, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$164.6M-$55.2M
FY2023$174.6M-$133.1M
FY2024$110.5M-$232.6M
FY2025$125.6M-$91.9M

Cash flows

FY2025: -$135.1M from operations, -$138.3M free after investment (dashed).

Xencor, Inc. operating and free cash flow by fiscal year
Xencor, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$24.5M-$18.9M
FY2023-$77.9M-$99.2M
FY2024-$202.2M-$211.7M
FY2025-$135.1M-$138.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$125.6M+13.7%1Y
EBITDA
-$47.2M
Net profit
-$91.9M
Cash from operations
-$135.1M
Free cash flow
-$138.3M
Revenue CAGR, 3Y
-8.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$125.6M-$47.2M-$91.9M-$138.3M-14.5%+13.7%-60.5%

Monthly returns

Month-by-month returns of XNCR across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$875.5M
Liabilities$239.9M
Equity$635.6M
Paid-in capital$1.4B
Retained earnings-$796.0M
Minority interest$0.00

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; XNCR highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Xencor, Inc. (this company)4.2x

Not shown (no positive earnings and no EV / Sales): Annexon, Inc., Cullinan Therapeutics, Inc., Jade Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Xencor, Inc.XNCRthis company$890.4M—1.4x-14.5%—
ARS Pharmaceuticals, Inc.SPRY$900.7M-5.3x7.9x-149.9%-5.7x
Annexon, Inc.ANNX$892.9M-4.3x4.2x-97.7%-3.5x
Pacira BioSciences, Inc.PCRX$892.0M126.9x1.3x1.0%8.7x
Cullinan Therapeutics, Inc.CGEM$886.8M-4.0x2.2x-53.8%-3.3x
MeiraGTx Holdings plcMGTX$886.3M-7.8x-153.0x1971.4%-10.2x
Jade Biosciences, Inc.JBIO$875.6M—-18.7x-38.3%—
Certara, Inc.CERT$872.7M-547.2x0.8x-0.2%9.7x
Talkspace, Inc.TALK$871.1M111.8x7.4x6.7%129.1x
Peer median—-4.3x1.7x-19.2%-3.3x

Year-to-date ROI

XNCR since 1 January, against earlier years.

Historical volatility

XNCR's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Xencor, Inc. operating margin by fiscal year
Xencor, Inc. operating margin by fiscal year
DateOperating margin
FY2022-50.1%
FY2023-75.8%
FY2024-161.5%
FY2025-141.3%
LineFY2025
Operating expensesOperating Expense$303.1M
Research and developmentResearch And Development$239.4M
Total expensesTotal Expenses$303.1M
Pretax incomePretax Income-$89.6M

Learn while you research

Academy chapters picked for Xencor, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →